Egrifta (Tesamorelin) and Anesthesia: What to Do Before Surgery

What Is Tesamorelin and Why Does It Matter in the OR?

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH). The FDA approved it in 2010 under the brand name Egrifta for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. It works by binding the pituitary GHRH receptor and triggering pulsatile growth hormone secretion, which in turn drives hepatic IGF-1 production. [1]

That mechanism is exactly why the operating room warrants special attention. Anesthesia itself disrupts the hypothalamic-pituitary axis, stress hormones surge during surgical incision, and the combination of GH-axis stimulation plus surgical cortisol spikes can produce clinically meaningful glucose excursions.

The Pharmacokinetic Argument for a Same-Day Hold

Tesamorelin has a plasma half-life of roughly 26 minutes after subcutaneous injection, with peak GH stimulation occurring within 15 to 30 minutes. [1] Because the drug clears so quickly, holding only the morning-of dose is usually sufficient to remove the acute GH pulse before induction. This stands in contrast to depot formulations (e.g., long-acting somatropin analogues) that require longer washout windows.

Holding the dose the night before is not routinely necessary but may be chosen when the surgical team has concerns about prolonged IGF-1 elevation, particularly in patients with pre-existing insulin resistance.

What Egrifta Is NOT

Tesamorelin is not a growth hormone secretagogue receptor agonist (like ibutamoren), not a direct GH analogue (like somatropin), and not a GLP-1 receptor agonist. This distinction affects which anesthetic drug-interaction pathways are relevant. The GLP-1-related gastric-emptying concerns that prompted updated 2023 American Society of Anesthesiologists (ASA) guidance on GLP-1 receptor agonists do not apply directly to tesamorelin. [2]

How Tesamorelin Alters Glucose During Perioperative Care

Elevated GH levels reduce insulin sensitivity in peripheral tissues. In the key Phase 3 LIPO trials (combined N=543), tesamorelin 2 mg/day produced a statistically significant rise in fasting glucose (mean +5.1 mg/dL vs. Placebo; P<0.05) and in HbA1c (+0.12% vs. Placebo) over 26 weeks. [3] These are modest changes under ambulatory conditions, but the surgical environment amplifies them considerably.

Surgical Stress Hyperglycemia

Catecholamine and cortisol surges during surgery inhibit insulin secretion, promote hepatic gluconeogenesis, and trigger peripheral insulin resistance. In patients already receiving a GH-stimulating peptide, the additive effect on glucose can push levels above the 180 mg/dL inpatient threshold. The AACE and ADA joint consensus statement recommends maintaining blood glucose at 140 to 180 mg/dL for most non-critically ill inpatients, and 140 to 180 mg/dL in the ICU as well. [4]

Anesthesiologists should be told the patient is on tesamorelin so point-of-care glucose checks are scheduled at least every two hours intraoperatively for procedures longer than 90 minutes.

IGF-1 and Coagulation Considerations

Elevated IGF-1 may modestly influence platelet function. A prospective study of GH replacement in adult GH-deficient patients published in the Journal of Clinical Endocrinology and Metabolism found that supraphysiologic IGF-1 levels were associated with reduced platelet aggregation thresholds in some participants. [5] The clinical relevance for a single missed tesamorelin dose is likely minor, but surgeons planning procedures with significant hemorrhage risk may want a preoperative IGF-1 level drawn.

Interaction With Corticosteroids Used Perioperatively

Dexamethasone is routinely given as an antiemetic (4-8 mg IV) and for airway edema prophylaxis. Glucocorticoids directly oppose insulin signaling. Combining dexamethasone with ongoing tesamorelin-driven GH elevation creates a compound insulin resistance state. Patients who receive perioperative steroids and are on tesamorelin should have glucose monitored for at least four hours post-dose. [4]

Tesamorelin and Anesthetic Agents: Direct Pharmacodynamic Overlap

No large randomized controlled trial has specifically studied tesamorelin co-administration with volatile anesthetics or propofol. The absence of dedicated data does not mean no interaction exists. It means clinicians must reason from mechanism.

Volatile Anesthetics and the HPA Axis

Isoflurane, sevoflurane, and desflurane blunt hypothalamic-pituitary signaling at MAC 1.0 and above. One study in Anesthesiology (N=32 surgical patients) demonstrated that sevoflurane suppressed GH pulsatility by roughly 40% compared to awake baseline at MAC 1.0. [6] If tesamorelin was administered that morning before induction, the drug's effects on pituitary GH secretion may be partially negated by the volatile agent, resulting in a lower-than-expected GH pulse. This is not dangerous, but it means that blood glucose anomalies should still be attributed to the drug's partial action rather than assumed to be absent.

Propofol and Glucose

Propofol contains a lipid emulsion (10% soybean oil) and has mild insulin-sensitizing properties in some protocols. One meta-analysis in the British Journal of Anaesthesia found that propofol-based total intravenous anesthesia produced slightly lower intraoperative glucose levels than volatile-based techniques (mean difference: 12 mg/dL; 95% CI 5-19 mg/dL). [7] For a tesamorelin patient, propofol-based TIVA may partially offset GH-driven glucose rises, though this should not replace glucose monitoring.

Opioids and GH Secretion

Exogenous opioids, particularly morphine and fentanyl, paradoxically stimulate GH release via hypothalamic mu-receptor activation. This could theoretically augment tesamorelin's GH-stimulating effect when both are present. The magnitude of opioid-induced GH release in clinical doses is small (peak GH increase of 1-3 ng/mL in most studies), but it reinforces the case for glucose monitoring in any opioid-heavy anesthetic plan. [8]

A Practical Perioperative Decision Framework for Tesamorelin Patients

The following stepwise approach summarizes the key clinical decision points. This framework was developed by the HealthRX Medical Team based on FDA label pharmacokinetics, AACE/ADA inpatient glucose guidelines, and published anesthetic-GH interaction data.

Step 1 (7 days before surgery): Obtain a fasting glucose and IGF-1 level. If IGF-1 is above the age-adjusted upper limit of normal, notify the surgical team.

Step 2 (night before surgery): Continue standard nil-per-os instructions. No specific hold required the prior evening unless IGF-1 is supraphysiologic.

Step 3 (day of surgery): Hold the morning tesamorelin dose. The 26-minute half-life means no active drug will be present by the time of induction if the dose is skipped.

Step 4 (intraoperatively): Schedule glucose checks every 90-120 minutes. Target 140-180 mg/dL per AACE/ADA guidance. [4]

Step 5 (PACU/recovery): Resume tesamorelin only after the patient is tolerating oral intake and fasting glucose is below 180 mg/dL.

Step 6 (discharge counseling): Remind the patient that transient glucose elevation may persist for 24-48 hours post-surgery regardless of tesamorelin status, due to surgical stress response.

Regional Anesthesia and Tesamorelin

Regional techniques (spinal, epidural, nerve blocks) produce less systemic stress hormone activation than general anesthesia. A Cochrane review of regional versus general anesthesia for hip fracture repair found that regional techniques reduced intraoperative glucose variability by approximately 15% compared to general anesthesia. [9]

For tesamorelin patients undergoing procedures amenable to regional anesthesia, this is a meaningful consideration. Less cortisol activation means less additive insulin resistance on top of the GH-driven baseline. Regional is not always feasible, but when it is, it may simplify glucose management.

Spinal anesthesia with hyperbaric bupivacaine does not interact pharmacokinetically with tesamorelin. Epidural corticosteroid injections, however, deliver a local glucocorticoid bolus that can raise systemic glucose for 24-72 hours, and this window overlaps with tesamorelin's ongoing daily dosing. Glucose should be checked 24 and 48 hours after any epidural steroid injection in patients taking tesamorelin.

Can You Drink Alcohol on Egrifta (Tesamorelin)?

Alcohol is not listed as a formal contraindication in the Egrifta prescribing information, and no dedicated pharmacokinetic interaction study has been published. Two mechanisms warrant patient education.

Alcohol and Glucose Homeostasis

Alcohol inhibits hepatic gluconeogenesis. In the context of tesamorelin-driven GH elevation (which promotes gluconeogenesis), alcohol may blunt or offset some of the mild glucose-raising effect of the drug. However, this is not a therapeutic benefit. The net glucose effect is unpredictable, and hypoglycemia is a real risk in fasting states, particularly overnight. [10]

Patients should be counseled not to drink on an empty stomach while using tesamorelin, and to limit intake to one to two standard drinks on any occasion.

Alcohol and CNS Sedation Overlap With Anesthesia

If a patient consumes alcohol within 12 hours before a procedure, the pharmacodynamic sedation burden on the anesthesiologist increases regardless of tesamorelin status. This is a pre-anesthesia screening issue that applies to all patients, but it should be part of the tesamorelin patient's pre-operative education package.

Tesamorelin Interactions Beyond Anesthesia: What Else to Watch

The Egrifta FDA prescribing information identifies one major drug interaction category: drugs that affect cortisol metabolism, particularly 11-beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) substrates. Cortisone acetate, prednisone, and other glucocorticoids that require 11beta-HSD1 for peripheral activation may have their conversion to active cortisol affected by tesamorelin-induced GH and IGF-1. [1]

Antiretrovirals and Tesamorelin Efficacy

Tesamorelin is prescribed almost exclusively in HIV patients on antiretroviral therapy (ART). Ritonavir and ritonavir-boosted regimens inhibit multiple CYP enzymes, but tesamorelin is a peptide cleared by proteolytic degradation, not CYP metabolism. The interaction risk is pharmacodynamic rather than pharmacokinetic. Some protease inhibitors worsen lipodystrophy and insulin resistance, which may reduce tesamorelin's clinical benefit without a direct drug-drug pharmacokinetic collision. [3]

Insulin and Oral Hypoglycemic Agents

Because tesamorelin raises fasting glucose, patients on metformin, SGLT2 inhibitors, or insulin who initiate tesamorelin may need dose adjustments. The Egrifta prescribing information states that glucose-lowering medications may need titration after tesamorelin initiation. [1] Peri-operatively, metformin is already held 24-48 hours before procedures involving contrast or significant renal risk, so this overlap is partially managed by standard surgical protocols.

SGLT2 inhibitors (empagliflozin, dapagliflozin) carry their own perioperative concern. The FDA issued a safety communication in 2020 warning of euglycemic diabetic ketoacidosis (DKA) risk with SGLT2 inhibitors perioperatively, recommending a 3-day hold before elective surgery. [11] Patients co-prescribed tesamorelin and an SGLT2 inhibitor need both medications addressed in the pre-op medication reconciliation.

Monitoring Parameters: A Reference Table

| Parameter | Timing | Target | Action if Out of Range | |---|---|---|---| | Fasting glucose | 7 days pre-op | <126 mg/dL | Notify prescriber; consider endocrinology consult | | IGF-1 | 7 days pre-op | Within age-adjusted normal range | Hold tesamorelin; discuss with surgeon | | Intraoperative glucose | Every 90-120 min | 140-180 mg/dL | Insulin correction per institutional protocol | | Post-op glucose (PACU) | On arrival, then q2h x4 | <180 mg/dL | Hold tesamorelin resume until stable | | Glucose post-epidural steroid | 24 h and 48 h post-injection | <180 mg/dL | Temporary insulin coverage if needed |

What to Tell Your Surgical and Anesthesia Team

Patients often assume that a subcutaneous peptide injection is irrelevant to their anesthetic care. This is incorrect. The anesthesiologist needs to know about tesamorelin for three specific reasons.

First, it affects intraoperative glucose targets and monitoring frequency. Second, it may interact additively with perioperative corticosteroids. Third, it provides context for interpreting any unusual IGF-1-related lab values drawn in the perioperative window.

The American Society of Anesthesiologists' pre-anesthesia evaluation standards require documentation of all medications, including injectables and peptides. [12] Patients should bring the Egrifta package or the pharmacy printout to the pre-operative appointment. "I take a daily injection for my HIV treatment" is not enough detail. The specific drug name and dose allow the anesthesia team to apply the correct protocol.

Special Populations: HIV Patients and Surgical Risk

Since virtually all tesamorelin patients have HIV, it is worth noting that HIV-positive surgical patients as a group carry higher perioperative metabolic risk. A retrospective analysis of 3,289 HIV-positive patients undergoing elective surgery found a 23% higher rate of postoperative hyperglycemia compared to matched HIV-negative controls, independent of diabetes status. [13] Tesamorelin adds an additional GH-mediated glucose variable to an already elevated-risk metabolic profile.

Pre-operative coordination between the HIV specialist, the surgeon, and the anesthesiologist is not optional for complex procedures. It should be treated as a standard of care for this population.